Pharmacy and Pharmaceutical Sciences Commons^™

Advocate Aurora Apc Grand Rounds Dm Pharm Update 7 2019 Chojnacki.Pptx, Carl Chojnacki

Carl Chojnacki, MBA, MSN, APNP, ANP-BC, AWLS

The Impact Of Free Health Screenings At Community Pharmacies On Diabetes, Anna M. Staudt, Nicholas C. Daniels, Jessica E. Amtower, Jeniffer George, Jacques N. Allou, Jeb Ballentine, Emily M. Laswell

Anna Staudt, Pharm.D.

Background: Health screenings can be beneficial when looking to detect diseases early on, thus making treatment easier. Free health screenings are typically performed in the community pharmacy setting. This makes it convenient because it is easily accessible and there is no appointment required. Diabetes is currently one of the most significant health issues faced today, with an estimated 7 million Americans going undiagnosed. Health screenings in community pharmacies are valuable to detect high blood glucose levels for patients to be referred for diagnosis and treatment. Previous studies related to health screenings have focused on hypertension and cholesterol, and few have …

The Impact Of Free Health Screenings At Community Pharmacies On Diabetes, Jeb Ballentine, Emily M. Laswell, Anna M. Staudt, Jacques N. Allou, Jeniffer George, Jessica E. Amtower, Nicholas C. Daniels

Anna Staudt, Pharm.D.

Diabetes is a prevalent issue in the United States, with an estimated 8.1 million people un-diagnosed as of 2012. Health screenings have been proven to identify diseases earlier, thereby resulting in earlier and more satisfactory treatment. Community pharmacies can offer many of the same screenings as those in doctor offices. The objective of this study was to assess the impact of free health screenings in community pharmacies on patient follow-up, perceptions, and knowledge of diabetes through blood glucose screenings and patient education. The study design was a pre-post observational study using surveys, blood sugar screenings, and patient education on diabetes. …

Glp-1 Agonists In Type 1 Diabetes Mellitus: A Review Of The Literature, Kristin M. Janzen, Taylor D. Steuber, Sarah A. Nisly

Sarah A. Nisly

Objective: To review the use of GLP-1 agonists in patients with type 1 diabetes mellitus (T1DM). Data Sources: A search using the MEDLINE database, EMBASE, and Cochrane Database was performed through March 2016 using the search terms glucagon-like peptide 1 (GLP-1) agonists, incretin, liraglutide, exenatide, albiglutide, dulaglutide, type 1 diabetes mellitus. Study Selection and Data Extraction: All English-language trials that examined glycemic end points using GLP- 1 agonists in humans with T1DM were included. Data Synthesis: A total of 9 clinical trials examining the use of GLP-1 agonists in T1DM were identified. On average, hemoglobin A1C (A1C) was lower than …